Phase I study of nonpegylated liposomal doxorubicin plus trastuzumab in patients with HER2-positive breast cancer

Clinical Breast Cancer

Volumn 9, Issue 2, 2009, Pages 101-107

  Theodoulou, Maria ^a   Batist, Gerald ^b   Campos, Susana ^c   Winer, Eric ^c   Welles, Lauri ^d   Hudis, Clifford ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d Cephalon   (France)

Author keywords

Cardiac toxicity; Congestive heart failure; Left ventricular ejection fraction; Neutropenia

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GRANULOCYTE COLONY STIMULATING FACTOR; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; ASTHENIA; BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HORMONAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; LOADING DRUG DOSE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; ONCOGENE NEU; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMATITIS; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; BREAST TUMOR; CANCER STAGING; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DOXORUBICIN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 67649823616     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2009.n.019     Document Type: Article

References (27)

1. Gusterson B, Gelber R, Goldhirsch A, et al. Prognostic importance of c-erB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 1992; 10:1049.
2. Press M F, Pike MC, Chazin VR, et al. HER-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 1993; 53:4960-70.
3. Slamon D, Clark GM, Wong S, et al. Human breast cancer: correlation or relapse and survival amplification of the HER-2/neu oncogene. Science 1987; 235:177-82.
4. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244:707.
5. Henderson IC, Allegra JC, Woodcock T, et al. Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 1989; 7:560-71.
6. Paridaens R, Biganzoli L, Bruning P, et al. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer randomized study with cross-over. J Clin Oncol 2000; 18:724-33.
7. Praga C, Beretta G, Vigo PL, et al. Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep 1979; 63:827-34.
8. VonHof D, Layard M, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91:710-7.
9. Pharmacia Corporation. Adriamycin (doxorubicin hydrochloride) prescribing information, 2000.
10. Balazsovits JA, Mayer LD, Bally MB, et al. Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin. Cancer Chemother Pharmacol 1989; 23:81-6.
11. Cowens J W, Creaven PJ, Greco WR, et al. Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes). Cancer Res 1993; 53:2796-802.
12. Conley BA, Egorin MJ, Whitacre MY, et al. Phase I and pharmacokinetic trial of lipsome-encapsulated doxorubicin. Cancer Chemother Pharmacol 1993; 33:107-12.
13. Kanter PM, Bullard GA, Ginsberg RA, et al. Comparison of the cardiotoxic effects of liposomal doxorubicin (TLC D-99) versus free doxorubicin in beagle dogs. In Vivo 1993; 7:17-26.
14. Keefe DL. Trastuzumab-associated cardiotoxicity. Cancer 2002; 95:1592-600.
15. Harris L, Batist G, Belt R, et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002; 94:25-36.
16. Batist G, Ramakrishnan G, Rao CS, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001; 19:1444-54.
17. Cobleigh M, Vogel C, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER 2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17:2639-48.
18. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20:719-26.
19. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-92.
20. Chien KR. Herceptin and the heart-a molecular modifier of cardiac failure. N Engl J Med 2006; 354:789-90.
21. Genentech Inc. Herceptin [package insert]. South San Francisco, CA; 2007.
22. Chia S, Clemons M, Martin L, et al. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial. J Clin Oncol 2006; 24:2773.
23. Untch M, Eidtmann H, du Bois A, et al. Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer; results of a phase I trial. Eur J Cancer 2004; 40:988-97.
24. Zhao YY, Sawyer DR, Baliga RR, et al. Neuregulins promote survival and growth or cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem 1998; 273:10261-9.
25. Theodoulou M, Hudis C. Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin? Cancer 2004; 100:2052-63.
26. Cortes J, Climent M, Lluch A, et al. Updated results of a phase II study (M77035) of nonpegylated liposomal doxorubicin combined with weekly Herceptin and paclitaxel in patients with HER-2-postiive locally advanced or metastatic breast cancer (LABC/MBC). Presented at: the 27th Annual Meeting of the San Antonio Breast Cancer Symposium; December 8-11, 2004; San Antonio TX.
27. Karabelis A, Kosmas C, Mylonakis G, et al. Paclitaxel, pegylated liposomal doxorubicin and trastuzumab as 1st line chemotherapy in HER-2/neu positive metastatic breast cancer. J Clin Oncol 2006; 24(18 suppl):581s (Abstract 10663).